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Abstract
Background: The aim of this study was to evaluate the prevalence of self-reported underuse of medications due to
procurement costs amongst older persons from seven European urban communities.
Methods: The data were collected in a cross-sectional study (“ABUEL, Elder abuse: A multinational prevalence
survey”) in 2009. Randomly selected people aged 60–84 years (n = 4,467) from seven urban communities: Stuttgart
(Germany), Athens (Greece), Ancona (Italy), Kaunas (Lithuania), Porto (Portugal), Granada (Spain) and Stockholm
(Sweden) were interviewed. Response rate - 45.2 %. Ethical permission was received in each country.
Results: The results indicate that 3.6 % (n = 162) of the respondents self-reported refraining from buying prescribed
medications due to cost. The highest prevalence of this problem was identified in Lithuania (15.7 %, n = 99) and Portugal
(4.3 %, n = 28). Other countries reported lower percentages of refraining from buying medications (Germany – 2.0 %,
Italy – 1.6 %, Sweden – 1.0 %, Greece – 0.6 %, Spain – 0.3 %). Females refrained more often from buying medications
than males (2.6 % vs. 4.4 %, p < 0.0001). The prevalence of this refraining tended to increase with economic hardship.
Discussion: These differences between countries can be only partly described by the financing of health-care systems.
In spite of the presence of cost reimbursement mechanisms, patients need to make co-payments (or in some cases to
pay the full price) for prescribed medications. This indicates that the purchasing power of people in 10.1186/s12913-015-
1089-4 the particular country can play a major role and be related with the economic situation in the country. Lithuania,
which has reported the highest refrain rates, had the lowest gross domestic product (at the time of conducting this
study) of all participating countries in the study.
Conclusions: Refraining from buying the prescribed medications due to cost is a problem for women and men in
respect to ageing people in Europe. Prevalence varies by country, sex, and economic hardship.
Keywords: Ageing, Accessibility, Medications, Europe, ABUEL
Background
The use of medicines by elderly people is a growing con-
cern in social pharmacy and beyond [1, 2]. In particular,
polypharmacy (the use of multiple medications) is com-
mon among the elderly but it may cause many problems
such as an increased risk of inappropriate use of medica-
tions/drugs, adverse effects and non-adherence. In addition,
polypharmacy increases medical costs [3]. Moreover,
increasing prices and the proportion of out-of-pocket
payments in purchasing necessary pharmaceuticals
may lead to situations where some older people refrain
from buying prescribed medications [4]. The World
Health Organization (WHO) has indicated five broad
groupings of potential reasons for medication non-
adherence: 1) patient, 2) health condition, 3) therapy,
4) socio-economic and 5) health system–related factors. In
particular socio-economic reasons include low health liter-
acy, poor social support and higher medication costs [5]. A
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review by Perkins (2002) showed that the correlation of
poor adherence were as follows: patients’ beliefs about their
illness/benefits of treatment, and barriers to treatment
such as easy access to treatment, family/social support
and perceived costs of treatment [6].
This non-adherence to medication use may cause serious
problems to the health status of patients and increased cost
to health-care systems in terms of additional hospital ad-
missions. For instance, data from Australia suggest that at
least 45,000 older Australians are hospitalized each year
because of medication-related problems, representing
20–30 % of unplanned hospital admissions for this age
group [7]. Non-adherence due to costs in the elderly,
could be of a significant and worrying size problem in
European countries. There have been several attempts to
measure the size of this problem in European countries
and beyond [8]. However, we still lack comparable data on
the refraining of purchasing medications due to cost.
In this paper we use data from a cross sectional study
in seven European countries (“Elder abuse: a multi-
national prevalence study – ABUEL” [9] project. One of
the objectives of this project was to measure the accessibil-
ity and use of health services by older people. The present
study is an opportunity to provide reliable data on the issue.
Basic characteristics of the healthcare system and pharma-
ceutical schemes in each country are presented in Table 1
[10–18]. Some papers on use and non-adherence have been
published elsewhere [19–22]. However, the referred papers
have examined the prevalence of refrain due to any cause
[19], or focused on the situation in Lithuania [20–22]. In
this paper, we investigate the prevalence of refrain due to fi-
nancial problems among older persons and to compare it
among seven European urban communities.
Methods
Data for this study were collected during the European
project ABUEL. The participants consisted of randomly
selected women and men from the general population
living in urban centres of seven European countries
(Germany; Stuttgart; Greece, Athens; Italy, Ancona;
Lithuania, Kaunas; Portugal, Porto; Spain, Granada;
Sweden, Stockholm), except for Greece where a ran-
dom route sample was used. Inclusion criteria were: 1)
aged 60–84 years; 2) did not suffer from dementia or
other cognitive impairments; 3) had a legal status (na-
tional citizens or documented migrants); 4) lived in
the community or sheltered houses; 5) could read and
write in the native languages; and 6) accepted partici-
pation to the study. A sample size was calculated
based on municipal censuses (women and men aged
60–84 years) and an expected abuse prevalence of
13 % derived from a recent systematic review [23].
The sample size was customized for each country
according to the population of individuals aged 60–84
years, with a maximum of 642 individuals in each of
the participating countries because of the infinite popula-
tion assumption. The sample was calculated proportional
to age–sex groups in the population in each city. Three
sampling approaches were used in ABUEL: 1) registry-
based sampling (Germany, Spain, Italy, Lithuania and
Sweden); 2) sampling by random route (Greece); and
3) cluster sampling (Portugal). The registry-based sam-
pling was based on the city’s population registries.
The total number of participants amounted to 4,451
(2,576 women, 57.9 %). Response rates in the sampling
base varied between countries from 18.9–87.4 %, with a
mean of 45.2 % across countries. Response rates for
women were 47.1 % and for men 49.3 %, and varied be-
tween age groups from 47.0–49.7 %, with a mean of
48 % across age groups.1 However, there were no major
differences (age and gender) between refusals and non-
refusals nor did they differ from the general population
in each participating country. The final sample consisted
of 4,467 persons (2,559 women, 57.3 %). A more detailed
description of sampling, data collection, and study limi-
tations are described in a separate ABUEL methodology
paper [24].
The design of the study was cross-sectional. Recruitment
and data gathering were performed during January-July,
2009. Written information about the ABUEL study was
sent to the eligible individuals’ homes. Trained interviewers
telephoned the eligible persons (except in Lithuania) and
provided information about the study. Informed consent
from participants was obtained before interviewing. Two
administration modes were used: (i) face-to-face interviews
(Spain, Italy, Greece, Lithuania, Portugal); and (ii) mixed
methods, i.e. face-to-face interviews and mailed question-
naires (Germany and Sweden).
Great emphasis was put on confidentiality, anonymity
and the rights of older persons. The ethical permissions
for the project were given by: Germany, Ethikkommis-
sion des Landes Baden-Wuerttenberg; Italy, Bioethics
Advisory Committee of National Institute of Health and
Science on Aging, Italian National Institute of Health
and Science on Aging; Lithuania, The Lithuanian State
Data Protection Inspectorate and the Kaunas Regional
Bioethics Committee; Portugal, Comité de Ética do Hos-
pital de João; Spain, Comité de Etica en Investigación de
la Universidad de Granada; and Sweden, Regional Ethical
Committee at Karolinska Institutet. In Greece, QED
(market research company) conducted the fieldwork under
the codes and guidelines of International Chamber of Com-
merce/European Society for Opinion and Market Research
which are similar to ethical provisions in the other partici-
pating countries.
The participants completed a standardized questionnaire
with various scales and questions [25]. Self-reported refrain
Stankuniene et al. BMC Health Services Research  (2015) 15:419 Page 2 of 8
Table 1 Basic characteristics of the healthcare system and pharmaceutical schemes in ABUEL study countries
Indicator Lithuania Sweden Germany Italy Spain Portugal Greece
Total health
expenditure
2011 as % of
GDP (PPP$ per
capita)1
6.66 % 9.62 % 11.28 % 9.18 % 9.62 % 9.46 % 9.28 %




of total health 20111






34.2 58.3 75.6 46.6 71.0 55.1 73.7
Predominant health
care financing mechanism2








to pay the full cost
for prescribed drugs,
up to SEK 1100 (€122),
after which level the
subsidy gradually






of €8.35 plus a fixed








by the SSN and involve
a modest co-payment
that varies across regions.6
I.e. Veneto Region implies
co-payment mechanism
from €2 for each packet












pay 40 % of the
retail price.8




from 90 % for category
A to 5 % for category D.
Pensioners have additional
reductions from 5 to 15 %.9
Insured citizens participate
in covering the cost of
pharmaceuticals with a
co-payment rate set at





beneficiaries of EKAS pay
a co-payment of 10 %. The
very poor are entitled to
pharmaceuticals provided
by public hospitals free of
charge.9
Surce:1 – Ref. 10;2 – Ref. 11;3–Ref. 12;4 – Ref. 13;5 – Ref. 14;6 – Ref. 15;7 - Ref. 16;8 - Ref 17,9 - Ref 18















from buying prescribed medications due to costs was mea-
sured with question: “What were the reasons for not buying
prescribed medications and care”? (multiple-choice). A spe-
cific time frame has not identified. Economic hardship was
measured with one question ”How often are you worried
about the daily expenses? (e.g. for buying food)” in a “never/
quite often/often/always” format. A participant was defined
as having “financial strain” if she/he chose any response
other than “never”.
Data were computed, coded and analyzed using the Stat-
istical Package for the Social Sciences for Windows, Version
17.0 (SPSS Inc.). The following statistical analyses were ap-
plied: 1) descriptive statistics; 2) logistic regression.
Associations of the reported refrain from buying pre-
scribed medications due to costs and social-economic
factors were measured calculating the prevalence of non-
adherence. Differences between groups were assessed by
using the two-tailed z criteria for categorical variables.
For evaluation of the impact of explanatory variables
on analyzed event, (binary dependent variable) Enter
model of multivariate logistic regression was used.
Dependent variable was the reported refrain from buy-
ing prescribed medications due to costs (based on answers
in the questionnaire). Sex, age, country of residence, living
alone, education, economic hardship were used as inde-
pendent variables. These associations were measured using
odds ratio (OR) and calculating the 95 % confidence inter-
val (CI). Differences in results at the p < 0.05 level were
considered statistically significant.
Results
Of the 4,467 respondents, 1,908 (42.5 %) were male and
2,559 (57.5 %) were female. The distribution of respon-
dents by age was: 60–64 years (25.2 %), 65–69 years
(24.4 %), 70–74 years (21.1 %), 75–79 years (16.1 %) and
80–84 years (12.2 %); and by education: cannot read/
write (3.1 %), without any degree (4.2 %), less than pri-
mary school (7.5 %), primary school/similar (24.4 %),
secondary school/similar (40.0 %), university/similar
(19.2 %) and other (1.6 %) (Table 2). A more detailed de-
scription of the study sample is presented in a separate
paper [26].
The results indicate that 3.6 % of all respondents of
the study had refrained from buying the prescribed med-
ications due to cost. Furthermore, prevalence varied by
country (Fig. 1). Cost-related non-adherence has been
Table 2 The main socio-demographic characteristics of respondents
Variable %/n
Lithuania Sweden Germany Italy Spain Portugal Greece All countries
Sex
Male 35.7/225 46.8/293 47.1/305 43.0/270 42.8/272 39.0/256 44.6/287 42.7/1908
Female 64.3/405 53.2/333 52.9/343 57.0/358 57.2/364 61.0/400 55.4/356 57.3/2559
Age group
60–64 years 23.2/146 33.9/212 21.7/137 22.5/141 23.3/148 24.5/161 27.8/179 25.2/1124
65–69 years 23.5/148 23.8/149 28.4/184 22.6/142 22.0/140 24.4/160 25.7/165 24.4/1088
70–74 years 23.2/146 16.9/106 23.5/152 20.5/129 22.5/143 21.0/138 22.9/147 21.5/961
74–79 years 19.2/121 13.3/83 16.0/104 18.9/119 17.8/113 17.5/115 14.6/94 16.8/749
80–84 years 11.0/69 12.1/76 11.0/71 15.4/97 14.5/92 12.5/82 9.0/58 12.2/545
Lives alone
No 75.8/475 66.1/414 67.3/429 86.9/546 82.14/522 78.4/514 73.7/474 75.8/3374
Yes 24.2/152 33.9/212 32.7/208 13.1/82 17.9/114 21.6/142 26.3/169 24.2/1079
Education
Less than primary 5.6/34 2.3/14 1.3/8 4.3/27 60.0/381 11.4/75 19.0/122 15.1/661
Primary 24.3/147 31.1/193 2.2/13 34.6/217 13.1/83 36.4/239 31.2/200 24.9/1092
Secondary 46.7/283 33.3/207 67.2/405 50.3/316 11.5/73 36.1/237 40.7/261 40.6/1782
University 23.4/142 33.3/207 29.4/177 10.8/68 15.4/98 16.0/105 9.0/58 19.5/855
Economic hardship
Never 26.8/169 64.0/400 52.5/339 41.4/259 31.8/202 29.7/195 6.4/41 36.0/1605
Quite often 37.8/238 26.4/165 31.7/205 35.8/224 9.9/63 23.0/151 23.5/151 26.8/1197
Often 21.4/135 5.4/34 11.5/74 15.3/96 15.1/96 11.3/74 28.1/181 15.5/690
Always 14.0/88 4.2/26 4.3/28 7.5/47 43.2/275 36.0/236 42.0/270 21.7/970
n number of observed persons
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identified in Lithuania 15.7 % (n = 99). The other coun-
tries reported considerably lower rates. The second high-
est rate was in Portugal (4.3 %, n = 28). The remaining
countries had prevalence rates lower than 2 %.
The prevalence of self-reported refrain from buying
medications was evaluated by different socio-economic
factors in each country and study sample in general
(Table 3). It was identified, that the prevalence of refrain
due to cost has differed by sex and economic hardship.
Females and people experiencing economic problems
were more likely not to buy prescribed drugs because of
costs. Age, education and living alone were not associ-
ated with refrain.
A logistic regression was used to estimate the risk fac-
tors involved in the occurrence of refrain from buying
prescribed medication due to cost (Table 4). The results
revealed that being from Lithuania and experiencing
economic hardship were related with increased risk to
refrain from buying prescribed medications due to cost
(OR = 14.92 and OR = 1.99 respectively).
Discussion
Our study revealed that the prevalence of refrain was
due to financial problems among older persons varied by
country from 0.3 % in Spain to 15.7 % in Lithuania.
Similar studies from other countries show variations by
country as well. The reported underuse of medicines due
to costs in older age varies from 3 % in the Australia,
Canada, New Zealand, and the Netherlands to 8 % in
Germany and 9 % in the United States [8].
Fig. 1 The prevalence (%) of refrain from buying medications by country
Table 3 The prevalence of refrain from buying medications due to cost by different socio-economic variables
Variable %/n
Lithuania Sweden Germany Italy Spain Portugal Greece All
Sex
Male (R) 16.0/36 0.7/2 1.6/5 0.7/2 0.0/0 1.6/4 0.0/0 2.6/49
Female 15.6/63 1.2/4 2.3/8 2.2/8 0.5/2 6.0/24** 1.1/4* 4.4/113***
Age group
60–64 years (R) 20.5/30 2.4/5 2.9/4 2.1/3 0.0/0 1.9/3 1.1/2 4.2/47
65–69 years 16.9/25 0.0/0* 0.5/1 2.1/3 0.7/1 3.8/6 0.6/1 3.4/37
70–74 years 12.3/18 0.9/1 3.9/6 2.3/3 0.0/0 5.8/8 0.7/1 3.9/37
74–79 years 14.0/17 0.0/0* 1.0/1 0.8/1 0.9/1 7.0/8 0.0/0 3.7/28
80–84 years 13.0/9 0.0/0* 1.4/1 0.0/0 0.0/0 3.7/3 0.0/0 2.4/13*
Lives alone
No (R) 16.4/78 0.7/3 0.9/4 1.5/8 0.2/1 3.3/17 0.6/3 3.4/114
Yes 13.2/20 1.4/3 4.3/ 9* 2.4/2 0.9/1 7.7/11 0.6/1 4.4/47
Education
Less than primary 26.5/9 7.1/1 0.0/0 0.0/0 0.3/1 17.3/13*** 0.0/0 3.6/24
Primary 17.7/26 1.6/3 7.7/1 0.9/2 1.2/1 4.2/10 0.5/1 4.1/45
Secondary 16.3/46 1.0/2 2.2/9 2.2/7 0.0/0 1.3/3 0.8/2 3.8/68
University (R) 11.3/16 0.0/0 1.7/3 1.5/1 0.0/0 1.9/2 0.0/0 2.6/22
Economic hardship
Never 3.0/5*** 0.3/1* 0.0/0* 0.8/2* 0.0/0 0.0/0*** 2.4/1 0.6/9***
Quite often 15.1/36* 0.0/0* 2.0/4* 0.4/1* 0.0/0 2.0/3* 0.0/0 3.7/44*
Often 24.4/33 2.9/1 5.4/4 2.1/2 0.0/0 13.5/10 0.0/0 7.2/50
Always (R) 28.4/25 15.4/4 17.9/5 10.6/5 0.7/2 6.4/15 1.1/3 6.1/59
n number of observed persons, R reference group
*-p < 0.05, **-p < 0,01 and ***-p < 0,001 comparing with a reference group
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How can these differences between ABUEL countries
be explained? It is noteworthy that all countries which
have participated in the study had pharmaceutical bene-
fit schemes. This suggests that the financing of health-
care systems can only partly explain differences in
refraining from buying prescribed medications among
older people. In spite of the presence of cost reim-
bursement mechanisms, patients need to make co-
payments (or in some cases to pay the full price) for
prescribed medications. In addition, studies indicate
that chronic diseases require significant proportions of
household incomes for buying medications [27]. This in-
dicates that the purchasing power of people in the particu-
lar country can play a major role and be related with the
economic situation in the country. Lithuania, which has re-
ported the highest refrain rates, had the lowest gross do-
mestic product (at the time of conducting this study) of all
participating countries in the study [28]. It could be that
economic factors influenced Lithuanians in deciding not to
use prescriptions prescribed by their doctors. It is note-
worthy that data for this study were collected during the
economic crisis in Lithuania. In 2009, Lithuania experi-
enced one of the highest annual decline of gross domestic
product in the European Union (−14.8 %) [29]. This “free
fall” of economy caused dramatic changes in salary pol-
icies, financing of health care and growth of unemploy-
ment [30]. It might be that “hard times” could have a
negative impact on the economic accessibility to medi-
cations as well. On the other hand, it should be men-
tioned that the Lithuanian Government cut old-age
pensions only from the year 2010 [31]. Therefore, we
think that the infl uence of crisis on respondents’ answers
is very limited. However, further investigations on this
issue are needed. Moreover, the similar situation has been
observed with accesibility to health care services within
this age group during the period of economic recession in
in Lithuania.
Our results show that the decision not to purchase
medications was linked to individuals experiencing fi-
nancial strain or problems. Similar patterns have been no-
ticed in studies from Australia, Canada, New Zealand,
United Kingdom and the United States [8].
We identified that females were more likely to refrain
from buying prescribed medications due to costs. An ex-
planation of this pattern could be that women in general
report more bodily distress, and more numerous, intense
and frequent somatic symptoms than men [32]. This
may cause women to use more pharmaceutical products
[20] and spend a considerable amount of the household
income on them. It could be that women decided not to
buy some of these prescribed medications in order to
save financial resources. Correa-De-Araujo et al. (2005)
showed that there are gender differences in use and ex-
penditure on prescription drugs amongst older adults
aged 65+. Overall, women spent about 17 % more than
average expenditures by men. Several authors demon-
strate evidence that it is critical for older women and
men to have proper access to prescribed medicines, par-
ticularly women, given the financial vulnerability of the
female population [33]. Moreover, Johnell and Parker
(2011) state that women and men express themselves
differently, report symptoms differently and probably
also are treated differently – encounter different behav-
ior – within the healthcare system. Socio-economic sta-
tus may also play a part, since women, at least elderly
women, often have a lower income and educational
level than men. Socio-economic status may be linked to
expectations, communication skills, how well informed
you are about various treatments, what demands you place
on healthcare and how you are treated within the health-
care system. It is therefore important to consider socio-
economic status (e.g. education level) in analyses of gender
differences, especially among elderly people [34].
The present study reveled inequalities in medication
accessibility between different countries and within coun-
tries. It suggests a much broader plan of actions for solving
this issue. Frost and Reich (2008) has developed a frame-
work to describe the components of access to new health
technologies, which can be adapted to accessibility to med-
ications. According to the authors, there are three key
components for improved access: availability (addressing
both “upstream” issues of product discovery and develop-
ment and “downstream” challenges of national pharma-
ceutical supply systems), affordability (sustainable funding
Table 4 Logistic regression analysis of the relation between refrain from buying prescribed medication due to cost and selected
socio-economic factors
Variable OR 95 % CI P
Being male 0.80 0.55-1.17 0.249
Age (each age group) 0.88 0.77-1.01 0.077
Education (higher level of education) 0.83 0.68-1.01 0.059
Living not alone 1.29 0.87-1.90 0.207
Being from Lithuania 14.92 10.33–21.56 P < 0.001
Daily worries about expenses (each group of more intensive worries) 1.99 1.68-2.35 P < 0.001
p significance level, OR odds ratio, CI confidence interval
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and low prices), and safe and effective medicine use (ra-
tional use, quality and safety) [35]. These key components
are affected by “architecture” of pharmaceutical system,
which includes financing pharmaceutical workforce, gov-
ernance, regulations etc. [36]. A complexity of this problem
requires political support and sustainability. The recent
WHO European policy framework and strategy for the
21st century “Health 2020” reminds about the commit-
ment of WHO and its Member States to ensure universal
coverage, including access to high-quality and affordable
care and medicines and to eliminate catastrophic and
impoverishing payments [37]. Some countries initiate
specific activities to achieve these political objectives.
Lithuania, which has demonstrated highest prevalence
in cost-related non-adherence, has approved the “Lithu-
anian Health Program 2014–2025” in 2014 [38]. This na-
tional health policy emphasizes the importance in
reducing health and health care (including accessibility to
medications) inequalities in the country. There are several
measures considered for this purpose but to name just
few, there are: increase of public funding of health care
system, strength of pharmaceutical care, use of health
technology asseement in developing a list of state reim-
bursed medicines.
This study has some limitations. The participants
(women and men) were recruited from urban centers
in seven European countries and results might not be
applicable to rural areas. Secondly, non-responders were
not investigated. It could be, that those who refrained
from buying prescribed medications were much higher
among those who refused. Third, some confounding ele-
ments have been identified in the questionnaire. The main
question of our paper is not asking, exclusively about
medicines, but about care as well. This could cause, that
answers reflect not only on medications. However, we ex-
pect only a minor effect of this factor, as the question is
placed in the group of questions related to use of medica-
tions. This could lead, that respondents answering this
question put more emphasis on mediations, rather other
care. The absence of a specific time frame for refrain,
could be identified as confounding factor as well. The
fourth, the accuracy of the data was dependent on the par-
ticipants’ subjective assessment of their situation. No ob-
jective evaluations (e.g. medical records) have been used
to corroborate their responses. More detailed discussion
on methodology and study limitations are published in a
separate paper [24].
Conclusions
The current study indicates that 3.6 % (n = 162) of older
people refrained from buying prescribed medications
due to cost. Living in Lithuania and financial strain were
associated with self-reported underuse of medicines due
to cost.
Non-adherence to medication prescribing occurs fre-
quently in Europe and is associated with adverse out-
comes and this impacts on patients, care providers and
the healthcare system. As Ho et al. have emphasized: “the
first step toward improving adherence, there needs to be a
broader recognition of the problem of non-adherence, and
once identified, simple strategies should be implemented in
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